Melody K. Schiaffino, PhD, MPH, Named Inaugural Moores Cancer Center, Associate Director for Equity, Diversity, and Inclusion
|
As the MCC Associate Director for Equity, Diversity, and Inclusion, Dr. Schiaffino will be responsible for fostering an inclusive and anti-racist environment for all members and employees of the Center by providing leadership to carry out a focused mission, vision, and strategy for DEI that aligns with the MCC Strategic Plan and DEI initiatives of UC San Diego Health, UC San Diego Health Sciences, and the larger UC San Diego campus. Read More»
|
|
|
Biden-Harris Administration Launches Initiative to Improve Cancer Outcomes in Low-Income Areas
|
On Monday, June 26, the Biden-Harris Administration awarded $50 million to launch the Persistent Poverty Initiative, an initiative to alleviate the cumulative effects of persistent poverty on cancer outcomes by building research capacity, fostering cancer prevention research, and promoting the implementation of community-based programs. Read More»
|
Moores Office of Translational Science Speed Networking Initiative
|
Unleash the power of collaboration with the Speed Networking Initiative, which fosters collaboration and facilitates the advancement of translational research. If you are seeking collaborators on your project and require assistance, then complete the form provided below by July 30, 2023. Moores OTS will facilitate the process of connecting you with up to 10 investigators who may be potential collaborators. Complete Form»
|
|
|
June 27, 2023 | 7:00 p.m.
|
July 25, 2023 | 3:00 p.m. ET
Zoom
|
August 1 – August 4, 2023
|
| |
NCI Cancer Prevention Fellowship Program
|
Applications for this postdoctoral fellowship program are open through August 1, 2023.
|
|
Applications for KL2 Mentored Career Development Award Now Open!
|
The ACTRI KL2 award is a mentored career development award that provides up to $120K toward salary, plus benefits, along with $25K per year in research funds. Successful applicants will receive up to 3 years of support. Applications for this program are open through August 15, 2023.
|
|
|
FEATURED FUNDING OPPORTUNITIES |
The goal of these Research Grants and Fellowships Programs is to identify and provide funding for innovative projects that exhibit the potential to make substantial contributions to cancer prevention and early detection. The Prevent Cancer Foundation defines cancer prevention as the “reduction of cancer incidence through research, education, and early detection.” Both Research Grants and Fellowships Programs will be awarded for 2 years at $50,000 per year, for a total of $100,000.
Deadline: Tuesday, July 11, 2023
|
This award funds innovative basic, applied, and translational cancer research to support Service members, their families, and the American public for 20 Congressionally directed cancer and disease topic areas. The PRCRP cannot fund research in cancers which have a dedicated research program at CDMRP including: breast, prostate, ovarian, lung, pancreatic, kidney, or melanoma. CDMRP also has a rare cancer program, however the PRCRP can fund research on rare cancers or rare cancer subtypes for cancer topics which are topics named in the PRCRP program.
Deadline: Tuesday, July 25, 2023
|
This RFA will fund up to $500,000 for a research proposal featuring novel technology or new approaches for target discovery or treatment in gastroesophageal cancer. Grantees will gain access to a supply of gastroesophageal cell lines, patient-derived organoids, and mouse models to facilitate research projects.
Deadline: Tuesday, August 1, 2023
|
This retention-focused, institutionally-supported program is intended to support under-represented minority faculty members in submitting successful resubmissions of NIH K or R (or equivalent) grant applications. The goal of the SUSTAIN program is to increase the likelihood of successful proposal resubmission by providing protected time, grant writing training, and linkage to didactic, mentorship, and other resources, which are customized to the applicant. The SUSTAIN program provides 1 to 2 years of support at 50% of full-time salary (up to $60,000), which must be matched by the department and confirmed in a letter from the candidate’s Department Chair. The combined effort must enable a total of at least 75% research effort.
Deadline: Friday, September 1, 2023
|
|
|
Journal of Clinical Oncology
Shumei Kato (Structural and Functional Genomics)
|
Gastroenterology
John M. Carethers (Cancer Control Program)
|
Journal of Hepatology
Gen-Sheng Feng (Cancer Biology and Signaling)
|
|
|
NRG-GU009: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT)
|
XL092-303: A Randomized Open-Label Phase 3 Study of XL092 Atezolizumab vs. Regorafenib in Subjects With Metastatic Colorectal Cancer
|
PI: Aaron Miller
NCT: NCT05425940
|
|
|
COMMUNITY OUTREACH AND ENGAGEMENT |
New Study - HPV Vaccine Misperceptions Among Hispanics/Latinos in Southern California
|
COE & CCP leaders Dr. Elena Martinez, Dr. Jesse Nodora, Dr. Corinne McDaniels-Davidson and Dr. Noe Crespo published new research in the Journal of Racial and Ethnic Disparities titled "HPV Vaccine Misperceptions Among Hispanics/Latinos in Southern California". The study found that "Hispanics/Latinos had a 3.03-point higher HPV vaccine misperception sum score relative to non-Hispanic whites, indicating greater agreement with misperceptions", and the authors advised that "culturally relevant interventions are needed to address HPV vaccine misperceptions among Hispanics/Latinos as part of efforts toward HPV-associated cancer health equity."
|
Cancer Prevention in the Trans and Nonbinary Community
|
The COE concluded its first two sessions of a new partnered series, "Cancer Prevention in the Trans and Nonbinary Community" in June. Co-hosted and co-developed with the San Diego Center for AIDS Research (CFAR) Trans and Nonbinary Advisory Board (TCAB), the series featured UCSD Health experts in gender affirming care, primary care, oncology and infectious disease. 62 community members joined us over two sessions, and 90% of individuals surveyed rated the series as very good or excellent. The COE is planning a third in-person educational session this summer, and is focused on sustaining LGBTQIA+ community input on UC San Diego Moores Cancer Center services.
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.
|
3855 Health Sciences Drive MC 0698 | La Jolla, CA 92093 US
|
|
|
This email was sent to sjchristie@ucsd.edu.
To continue receiving our emails, add us to your address book.
|
|
|
|
